Progenics Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:PGNX)

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. The biotechnology company earned $5.61 million during the quarter, compared to analysts' expectations of $7.05 million. Progenics Pharmaceuticals had a negative net margin of 311.63% and a negative return on equity of 91.96%. View Progenics Pharmaceuticals' Earnings History.

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Progenics Pharmaceuticals.

4 brokers have issued 1-year price targets for Progenics Pharmaceuticals' shares. Their forecasts range from $6.50 to $14.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $10.17 in the next twelve months. This suggests a possible upside of 76.5% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.

News headlines about PGNX stock have trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Progenics Pharmaceuticals.

Progenics Pharmaceuticals saw a drop in short interest in October. As of October 31st, there was short interest totalling 7,060,000 shares, a drop of 32.2% from the September 30th total of 10,410,000 shares. Based on an average daily trading volume, of 1,250,000 shares, the short-interest ratio is currently 5.6 days. Currently, 9.1% of the company's shares are short sold. View Progenics Pharmaceuticals' Current Options Chain.

Some companies that are related to Progenics Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Vonage (VG), Exelixis (EXEL), Caterpillar (CAT), Imax (IMAX), Novavax (NVAX), Portola Pharmaceuticals (PTLA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and Opko Health (OPK).

Progenics Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Eagle Asset Management Inc. (5.20%), Rice Hall James & Associates LLC (2.05%), Rhumbline Advisers (0.30%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.16%) and State of Alaska Department of Revenue (0.08%). Company insiders that own Progenics Pharmaceuticals stock include Lte Partners, Llc and Velan Capital, LP. View Institutional Ownership Trends for Progenics Pharmaceuticals.

PGNX stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC and Alps Advisors Inc.. View Insider Buying and Selling for Progenics Pharmaceuticals.

PGNX stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, California Public Employees Retirement System, State of Tennessee Treasury Department, Eagle Asset Management Inc. and Rhumbline Advisers. Company insiders that have bought Progenics Pharmaceuticals stock in the last two years include Lte Partners, Llc and Velan Capital, LP. View Insider Buying and Selling for Progenics Pharmaceuticals.

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PGNX stock can currently be purchased for approximately $5.76.

Progenics Pharmaceuticals has a market capitalization of $497.78 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.View Additional Information About Progenics Pharmaceuticals.

The official website for Progenics Pharmaceuticals is http://www.progenics.com/.

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]